Probiodrug to attend International Conferences in January 2017

Innovative Phase II study design of Glutaminylcyclase Inhibitor PQ912 in early Alzheimer’s disease
Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer’s disease patients